Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials
Introduction
Non-cystic fibrosis bronchiectasis (NCFB) is defined as an irreversible and progressive dilatation of bronchi due to chronic bronchial inflammation [1], [2]. The clinical presentations may range from no symptoms to chronic cough with frequent sputum production, hemoptysis, dyspnea, decreased exercise tolerance, frequent exacerbations [3], [4], respiratory failure, need for lung transplantation in some cases or death. Many pathological conditions can give rise to NCFB, including post-infection, foreign body aspiration, immunodeficiency, congenital abnormalities of the airway, and allergic bronchopulmonary aspergillosis [5], [6]. Although the etiologies are variable, the common pathophysiological pathway is a vicious cycle involving inflammation, infection, and repair of the bronchial mucosa. This pathogenic process causes destruction of the bronchial ciliated epithelium, loss of structural elements of the bronchial airway wall, such as elastin, and lesions in smooth muscle layers. The damaged airway ciliated epithelium impairs mucociliary clearance, and results in retention of secretions, which in turn attracts bacterial colonization, and predisposes the patient to repeated infections [1], [3], [7], [8], [9]. So the ultimate goal of bronchiectasis treatment is to break this vicious cycle, and prevent or retard progressive inflammatory lung damage.
Macrolides have been known for their antimicrobial activity since 1952, and are widely used to treat respiratory and soft tissue infections caused by Gram-positive bacteria, such as Streptococcus pneumoniae and Haemophilus influenzae, also rickettsiae, chlamydiae, and Mycoplasma pneumoniae, as well as some Gram-negative bacterial pathogens [10], [11]. Emerging evidence has shown that macrolides also have anti-inflammatory and immunomodulatory properties [10], [12], [13]. The benefits of macrolides in the treatment of diffuse panbronchiolitis and cystic fibrosis are well known [14], [15]. Several studies have also demonstrated the benefits of macrolides in bronchiectasis [16], [17]. But the efficacy and safety of long-term treatment with macrolides in patients with bronchiectasis have been controversial [18], [19]. The purpose of our study was to summarize the efficacy and safety of macrolide treatment in adults with NCFB through a meta-analysis of RCTs comparing prolonged macrolides therapy (for four or more weeks) with placebo.
Section snippets
Search strategy
We performed electronic searches of Pubmed, EMBASE, EBSCO, SCI, and the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6, 2013) databases. Published studies in these databases were collected from their inception up to August 2013.
We searched these databases using the search terms: bronchiectasis AND (macrolides OR anti-bacterial agents OR anti-mycobacterial agents OR antibiotics OR antimicrobials OR anti-inflammatory agents OR erythromycin OR azithromycin OR clarithromycin OR
Description of included studies
The process of study selection is illustrated in Fig. 1. Electronic searches yielded 834 references. After screening study titles and abstracts, and removing duplicates, 823 studies were excluded. Combined with references search, 11 studies were identified to be potentially relevant. After evaluation of full text, only four studies [20], [21], [22], [23] were found to be suitable according to the inclusion criteria, and were selected for analysis. Countries in which these studies were conducted
Discussion
Antibiotics are one of the main therapies for bronchiectasis during acute pulmonary exacerbations as well as the chronic stable phase. The importance of macrolides in NCFB is derived from their use in diffuse panbronchiolitis (DPB) and cystic fibrosis (CF). Macrolide maintenance therapy has been proven to benefit DPB [25] and CF [26], presumably due to their antimicrobial, anti-inflammatory and immunomodulatory properties. Macrolides are postulated to reduce airway inflammation by blocking the
Conclusions
In summary, this meta-analysis suggested that long-term treatment with low-dose of macrolides significantly reduced the incidence of pulmonary exacerbation and improved lung function in adults with NCFB, but could not improve quality of life and increased the rate of macrolide resistance. Moreover, macrolides could cause adverse effects, especially gastrointestinal complaints. Due to the many limitations of this meta-analysis, including limited number of included studies, population size of
Author contributions
Guang-Ying Zhuo: principal authorship of the article, contributed to conception and design of research question, drafting of the manuscript, study selection, data abstraction, data analysis, data interpretation, assessing the quality of the studies, critically revising the article for important intellectual content, and approving the final version of this manuscript.
Qing He: contributed to conception of research question, critically revising the article for important intellectual content, and
Declaration of conflicting interests
The authors declare that they have no conflicts of interests.
Funding
The authors received no financial support for this research.
References (41)
- et al.
Aetiology in adult patients with bronchiectasis
Respir Med
(2007) Bronchiectasis
Chest
(2008)- et al.
The role of azithromycin in patients with cystic fibrosis
Paediatr Respir Rev
(2010) - et al.
Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis
Respir Med
(2008) - et al.
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
Lancet
(2007) - et al.
Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005
Int J Antimicrob Agents
(2009) - et al.
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis
Pulm Pharmacol Ther
(2009) - et al.
Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action
Pharmacol Ther
(2008) - et al.
Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations
Respir Med
(2011)
Macrolides and ketolides: azithromycin, clarithromycin, telithromycin
Infect Dis Clin North Am
Quality-of-life determinants in patients with clinically stable bronchiectasis
Chest
Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis
Chest
Airway inflammation in cystic fibrosis
Chest
Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century
Postgrad Med J
Bronchiectasis
Tuberc Respir Dis
Bronchiectasis – diagnosis and treatment
Dtsch Arzteblatt Int
Effect of macrolide on lung function and computed tomography (CT) score in non-cystic fibrosis bronchiectasis
Acta Clin Belg
Microbes in bronchiectasis: the forest or the trees?
Am J Respir Crit Care Med
Non-cystic fibrosis bronchiectasis: its diagnosis and management
Arch Dis Child Educ Pract Ed
Cited by (30)
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial
2022, The Lancet Respiratory MedicineCitation Excerpt :Since pulmonary exacerbations in young children are associated with reduced lung function in later childhood,9 our observations suggest an option for preventing longer term pulmonary decline. Azithromycin effects pulmonary exacerbations in other chronic respiratory conditions including non-cystic fibrosis bronchiectasis,30 chronic obstructive pulmonary disease,31 asthma,32 preschool wheezing,33 and primary ciliary dyskinesia.34 Since exacerbations are often triggered by respiratory viruses in these conditions, antiviral properties of azithromycin might reduce the effect of viral respiratory infections particularly in the first years of life when these infections are most common.
Bronchiectasis: Rising from its own ashes
2018, Archivos de BronconeumologiaComments on Zhuo etal.: Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials
2015, Pulmonary Pharmacology and TherapeuticsNon-anti-infective effects of antimicrobials and their clinical applications: A review
2015, Mayo Clinic ProceedingsCitation Excerpt :However, there was an increased rate of recovery of macrolide-resistant streptococci compared with placebo (27% vs 0.04%).27 A recent meta-analysis28 included the 3 aforementioned randomized clinical trials25-27 and another smaller trial by Tsang et al.29 The meta-analysis concluded that macrolide use was associated with significant improvement in lung function and reduced exacerbations in non-CF bronchiectasis but had no effect on quality of life. Only 3 studies had assessed the risk of macrolide resistance, and an increase in macrolide resistance was observed in 2 of them.28
Inaccurate data in my meta-analysis of prolonged macrolides for patients with non-cystic fibrosis bronchiectasis in adult
2014, Pulmonary Pharmacology and TherapeuticsInaccurate data in meta-analysis of macrolides by Guang-Ying etal
2014, Pulmonary Pharmacology and Therapeutics